



Australian Government
Department of Health
Therapeutic Goods Administration

Advisory Committee on Vaccines

Meeting Statement 12 - Wednesday 6 February 2019

Section A: Submissions for registration

The committee's advice was sought on one application seeking to extend the indication for the vaccine and also to register a new strength of this vaccine, and one application seeking to register an additional dosing schedule for the vaccine.

Further details of the ACV discussion and advice associated with this pre-market item may be released within the Australian Public Assessment Report (AusPAR). Please note that there is a delay between when an application is considered by the ACV and the publication of the AusPAR. To browse all AusPARs see [AusPAR search](#).

Section B: Safety

No safety or pharmacovigilance issue was discussed.

Section C: Immunisation Programs

No matter related to the immunisation programs was discussed.

Further information

For further information on the ACV, please visit [Advisory Committee on Vaccines](#) or contact the ACV by email ACV@health.gov.au.